Tracy A Battaglia1, Christine M Gunn2, Molly E McCoy1, Helen H Mu3, Amy S Baranoski4, Elizabeth Y Chiao5, Lisa A Kachnic6, Elizabeth A Stier3. 1. Women's Health Unit, Section of General Internal Medicine, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts. 2. Women's Health Unit, Section of General Internal Medicine, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts. Electronic address: Christine.Gunn@bmc.org. 3. Department of Obstetrics and Gynecology, Boston University Medical Center, Boston, Massachusetts. 4. Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania. 5. Department of Medicine, Baylor College of Medicine, Houston Health Services Research and Development Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas. 6. Department of Radiation Oncology, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts.
Abstract
BACKGROUND: Infection with the human immunodeficiency virus (HIV) remains associated with a greater risk of anal cancer, despite widespread use of combination antiretroviral therapy. Evidence concerning the acceptability of anal cancer screening gives little attention to women. Because HIV-infected women have a high prevalence of depression and history of sexual trauma, understanding acceptability among this group is critical. PURPOSE: We sought to assess barriers and motivators to participation in anal cancer screening research among a racial/ethnically diverse HIV-infected female population. METHODS: We conducted a survey based on the Health Belief Model to identify characteristics of women willing to participate in anal cancer screening research (n = 200). Bivariate analyses examined associations between willingness to participate and sociodemographics, clinical characteristics, and health beliefs. Logistic regression modeled willingness to participate in research. MAIN FINDINGS: Of the women who participated, 37% screened positive for depression, 43% reported a high trauma history, and 36% screened positive for posttraumatic stress disorder. Overall, 65% reported willingness to participate in research. Those likely to participate were older, reported intravenous drug use as their HIV risk factor, and had a history of prior high-resolution anoscopy (HRA) compared with those unwilling to participate. The most commonly reported barrier to anal Pap testing was fear of pain. In adjusted analyses, a lack of fear of pain and prior experience with HRA significantly predicted willingness to participate. CONCLUSIONS: Findings suggest that, to increase participation in anal Pap and HRA-related research for HIV-infected women, a single approach may not be adequate. Rather, we must harness patients' previous experiences and address psychosocial and financial concerns to overcome barriers to participation.
BACKGROUND:Infection with the human immunodeficiency virus (HIV) remains associated with a greater risk of anal cancer, despite widespread use of combination antiretroviral therapy. Evidence concerning the acceptability of anal cancer screening gives little attention to women. Because HIV-infectedwomen have a high prevalence of depression and history of sexual trauma, understanding acceptability among this group is critical. PURPOSE: We sought to assess barriers and motivators to participation in anal cancer screening research among a racial/ethnically diverse HIV-infected female population. METHODS: We conducted a survey based on the Health Belief Model to identify characteristics of women willing to participate in anal cancer screening research (n = 200). Bivariate analyses examined associations between willingness to participate and sociodemographics, clinical characteristics, and health beliefs. Logistic regression modeled willingness to participate in research. MAIN FINDINGS: Of the women who participated, 37% screened positive for depression, 43% reported a high trauma history, and 36% screened positive for posttraumatic stress disorder. Overall, 65% reported willingness to participate in research. Those likely to participate were older, reported intravenous drug use as their HIV risk factor, and had a history of prior high-resolution anoscopy (HRA) compared with those unwilling to participate. The most commonly reported barrier to anal Pap testing was fear of pain. In adjusted analyses, a lack of fear of pain and prior experience with HRA significantly predicted willingness to participate. CONCLUSIONS: Findings suggest that, to increase participation in anal Pap and HRA-related research for HIV-infectedwomen, a single approach may not be adequate. Rather, we must harness patients' previous experiences and address psychosocial and financial concerns to overcome barriers to participation.
Authors: María José Míguez; Ximena Burbano-Levy; Rhonda Rosenberg; Robert Malow Journal: J Assoc Nurses AIDS Care Date: 2011 Nov-Dec Impact factor: 1.354
Authors: Alison C Reed; Paul L Reiter; Jennifer S Smith; Joel M Palefsky; Noel T Brewer Journal: Am J Public Health Date: 2010-04-15 Impact factor: 9.308
Authors: Michael J Silverberg; Bryan Lau; Amy C Justice; Eric Engels; M John Gill; James J Goedert; Gregory D Kirk; Gypsyamber D'Souza; Ronald J Bosch; John T Brooks; Sonia Napravnik; Nancy A Hessol; Lisa P Jacobson; Mari M Kitahata; Marina B Klein; Richard D Moore; Benigno Rodriguez; Sean B Rourke; Michael S Saag; Timothy R Sterling; Kelly A Gebo; Natasha Press; Jeffrey N Martin; Robert Dubrow Journal: Clin Infect Dis Date: 2012-01-30 Impact factor: 9.079
Authors: Amy S Baranoski; Richa Tandon; Janice Weinberg; Faye F Huang; Elizabeth A Stier Journal: Am J Obstet Gynecol Date: 2012-03-30 Impact factor: 8.661
Authors: Thomas K Houston; Jeroan J Allison; Marc Sussman; Wendy Horn; Cheryl L Holt; John Trobaugh; Maribel Salas; Maria Pisu; Yendelela L Cuffee; Damien Larkin; Sharina D Person; Bruce Barton; Catarina I Kiefe; Sandral Hullett Journal: Ann Intern Med Date: 2011-01-18 Impact factor: 25.391
Authors: Joël Fokom Domgue; Craig Messick; Andrea Milbourne; Ming Guo; Mila P Salcedo; Kristina R Dahlstrom; Elizabeth Y Chiao; Ashish A Deshmukh; Erich M Sturgis; Kathleen M Schmeler Journal: Gynecol Oncol Date: 2019-03-01 Impact factor: 5.482
Authors: E Kaufman; C de Castro; T Williamson; B Lessard; M Munoz; M H Mayrand; A N Burchell; M B Klein; L Charest; M Auger; V Marcus; F Coutlée; A de Pokomandy Journal: Curr Oncol Date: 2020-02-01 Impact factor: 3.677
Authors: Robin T Higashi; Serena A Rodriguez; Andrea C Betts; Jasmin A Tiro; Amneris E Luque; Rachel Rivera; Arti Barnes Journal: AIDS Care Date: 2021-02-17
Authors: Serena A Rodriguez; Robin T Higashi; Andrea C Betts; Cynthia Ortiz; Jasmin A Tiro; Amneris E Luque; Arti Barnes Journal: J Low Genit Tract Dis Date: 2021-01-01 Impact factor: 3.842